We appreciate the interest of Wainberg and O’Reilly in our recently published News & Views article that critiques the design and reporting of results from the NAPOLI 3 trial (Nevala-Plagemann, C. & Garrido-Laguna, I. NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype? Nat. Rev. Clin. Oncol. 21, 567–568 (2024))¹. In their Correspondence (Wainberg, Z. A. & O’Reilly, E. M. NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3. Nat. Rev. Clin. Oncol. https://doi.org/10.1038/s41571-024-00952-5 (2024))², they raise several points that we would like to address.

我们感谢Wainberg和O'Reilly在我们最近发表的新闻与观点文章中的兴趣，该文章批评了NAPOLI 3试验的设计和结果报告（Nevala-Plagemann， C. & Garrido-Laguna， I. NALIRIFOX治疗转移性胰腺癌：希望还是炒作？Nat. Rev. Clin.Oncol.21， 567–568 （2024））¹.在他们的通信中（Wainberg， Z. A. & O'Reilly， E. M. NALIRIFOX 在转移性胰腺癌的前线：超越那不勒斯的证据 3.Nat. Rev. Clin.Oncol.https://doi.org/10.1038/s41571-024-00952-5 （2024））² 中，他们提出了我们想解决的几个问题。